Patents by Inventor Alberto BALLESTRERO

Alberto BALLESTRERO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of a fasting mimicking diet to enhance the efficacy of antiestrogens in cancer
    Patent number: 11963941
    Abstract: A compound having antiestrogenic activity is used in a method for the treatment of BC or other estrogen-responsive tumors in a human patient, wherein the method comprises subjecting the patient to a fasting mimicking diet for a period of 24-190 hours while the patient is being treated with the compound having antiestrogenic activity, which can be a selective estrogen receptor modulator (SERM), a selective estrogen receptor downregulator (SERD) or an aromatase inhibitor (AI).
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: April 23, 2024
    Assignees: UNIVERSITA' DEGLI STUDI DI, L-NUTRA INC.
    Inventors: Alessio Nencioni, Alberto Ballestrero, Patrizio Odetti, Fiammetta Monacelli, Irene Caffa, Valter Longo
  • Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
    Patent number: 10512648
    Abstract: A tyrosine kinase inhibitor (TKI) for use in a method for the treatment of cancer in a patient, wherein the method comprises subjecting the patient to reduced caloric intake, i.e a daily caloric intake reduced by 10-100%, including starvation, for a period of 24-190 hours and administering the tyrosine kinase inhibitor to the patient during such period; the tyrosine kinase inhibitor is preferably selected among Lapatinib, Crizotinib, Gefitinib, Erlotinib, Afatinib and Regorafenib.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: December 24, 2019
    Assignees: UNIVERSITÀ DEGLI STUDI DI GENOVA, L-NUTRA INC.
    Inventors: Alberto Ballestrero, Irene Caffa, Valter Longo, Alessio Nencioni, Patrizio Odetti, Franco Patrone
  • TYROSINE KINASE INHIBITORS FOR USE IN A METHOD OF TREATING CANCER IN ASSOCIATION WITH A REDUCED CALORIC INTAKE
    Publication number: 20190105323
    Abstract: A tyrosine kinase inhibitor (TKI) for use in a method for the treatment of cancer in a patient, wherein the method comprises subjecting the patient to reduced caloric intake, i.e a daily caloric intake reduced by 10-100%, including starvation, for a period of 24-190 hours and administering the tyrosine kinase inhibitor to the patient during such period; the tyrosine kinase inhibitor is preferably selected among Lapatinib, Crizotinib, Gefitinib, Erlotinib, Afatinib and Regorafenib.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 11, 2019
    Applicants: UNIVERSITÀ DEGLI STUDI DI GENOVA, L-NUTRA INC.
    Inventors: Alberto BALLESTRERO, Irene CAFFA, Valter LONGO, Alessio NENCIONI, Patrizio ODETTI, Franco PATRONE
  • USE OF A FASTING MIMICKING DIET TO ENHANCE THE EFFICACY OF ANTIESTROGENS IN CANCER
    Publication number: 20190038591
    Abstract: A compound having antiestrogenic activity is used in a method for the treatment of BC or other estrogen-responsive tumors in a human patient, wherein the method comprises subjecting the patient to a fasting mimicking diet for a period of 24-190 hours while the patient is being treated with the compound having antiestrogenic activity, which can be a selective estrogen receptor modulator (SERM), a selective estrogen receptor downregulator (SERD) or an aromatase inhibitor (AI).
    Type: Application
    Filed: February 14, 2017
    Publication date: February 7, 2019
    Applicants: UNIVERSITA' DEGLI STUDI DI GENOVA, L-NUTRA INC.
    Inventors: Alessio Nencioni, Alberto Ballestrero, Patrizio Odetti, Fiammetta Monacelli, Irene Caffa, Valter Longo
  • Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake
    Patent number: 10117872
    Abstract: A tyrosine kinase inhibitor (TKI) for use in a method for the treatment of cancer in a patient, wherein the method comprises subjecting the patient to reduced caloric intake, i.e a daily caloric intake reduced by 10-100%, including starvation, for a period of 24-190 hours and administering the tyrosine kinase inhibitorto the patient during such period; the tyrosine kinase inhibitor is preferably selected among Lapatinib, Crizotinib, Gefitinib, Erlotinib, Afatinib and Regorafenib.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: November 6, 2018
    Assignees: UNIVERSITÀ DEGLI STUDI DI GENOVA, L-NUTRA INC.
    Inventors: Alberto Ballestrero, Irene Caffa, Valter Longo, Alessio Nencioni, Patrizio Odetti, Franco Patrone
  • TYROSINE KINASE INHIBITORS FOR USE IN A METHOD OF TREATING CANCER IN ASSOCIATION WITH A REDUCED CALORIC INTAKE
    Publication number: 20170173020
    Abstract: A tyrosine kinase inhibitor (TKI) for use in a method for the treatment of cancer in a patient, wherein the method comprises subjecting the patient to reduced caloric intake, i.e a daily caloric intake reduced by 10-100%, including starvation, for a period of 24-190 hours and administering the tyrosine kinase inhibitorto the patient during such period; the tyrosine kinase inhibitor is preferably selected among Lapatinib, Crizotinib, Gefitinib, Erlotinib, Afatinib and Regorafenib.
    Type: Application
    Filed: March 30, 2015
    Publication date: June 22, 2017
    Applicants: UNIVERSITÁ DEGLI STUDI DI GENOVA, L-NUTRA INC.
    Inventors: Alberto BALLESTRERO, Irene CAFFA, Valter LONGO, Alessio NENCIONI, Patrizio ODETTI, Franco PATRONE